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The novel adipokine progranulin 
counteracts IL-1 and TLR4-driven 
inflammatory response in human 
and murine chondrocytes via 
TNFR1
Vanessa Abella1,2, Morena Scotece1, Javier Conde1, Verónica López1, Claudio Pirozzi1, 
Jesús Pino3, Rodolfo Gómez1, Francisca Lago4, Miguel Ángel González-Gay5,6 & 
Oreste Gualillo1
Progranulin (PGRN) is a recently identified adipokine that is supposed to have anti-inflammatory 
actions. The proinflammatory cytokine interleukin-1β (IL1β) stimulates several mediators of cartilage 
degradation. Toll like receptor-4 (TLR4) can bind to various damage-associated molecular patterns, 
leading to inflammatory condition. So far, no data exist of PGRN effects in inflammatory conditions 
induced by IL1β or lipopolysaccharide (LPS). Here, we investigated the anti-inflammatory potential 
of PGRN in IL1β- or LPS-induced inflammatory responses of chondrocytes. Human osteoarthritic 
chondrocytes and ATDC-5 cells were treated with PGRN in presence or not of IL1β or LPS. First, we 
showed that recombinant PGRN had no effects on cell viability. We present evidence that PGRN 
expression was increased during the differentiation of ATDC-5 cell line. Moreover, PGRN mRNA and 
protein expression is increased in cartilage, synovial and infrapatellar fat pad tissue samples from OA 
patients. PGRN mRNA levels are upregulated under TNFα and IL1β stimulation. Our data showed that 
PGRN is able to significantly counteract the IL1β-induced expression of NOS2, COX2, MMP13 and 
VCAM-1. LPS-induced expression of NOS2 is also decreased by PGRN. These effects are mediated, 
at least in part, through TNFR1. Taken together, our results suggest that PGRN has a clear anti-
inflammatory function.
Osteoarthritis (OA) is a multifactorial joint degenerative disease characterized by progressive destruction of artic-
ular cartilage, changes in subchondral bone, osteophyte formation and synovial inflammation. It is the most 
prevalent type of arthritis, but its aetiology is still largely unknown1. Although OA is commonly described as 
non-inflammatory disease, inflammation is recognized as contributing to the symptoms and progression of OA2. 
On the other side, obesity is an important risk factor for OA that may result in overloading of joints and by a 
chronic ‘low-grade inflammatory systemic state sustained by a dysregulation of adipokines in white adipose tissue 
and other peripheral tissues, including joint tissues, that can contribute to an altered immune and inflammatory 
response3,4. Several adipokines can also be produced by chondrocytes and act locally in cartilage homeostasis5,6.
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Progranulin (PGRN) is a recently identified adipokine7, also known as GP88, acrogranin, proepithelin, gran-
ulin/epithelin precursor (GEP) or PC cell-derived growth factor (PCDGF). PGRN is a 68–88 kDa secreted gly-
coprotein that is produced by a broad range of tissues, including human articular cartilage8 and adipose tissue7. 
PGRN has been implicated in a wide variety of biological functions, including wound healing9, bone regenera-
tion10, and inflammation11,12. It has been previously reported that PGRN levels were significantly elevated in car-
tilage of patients with OA and rheumatoid arthritis (RA)8. Moreover, serum levels of PGRN in RA patients were 
found to be significantly higher than those in age-matched healthy controls13. Recently, it has been demonstrated 
that PGRN levels are increased at local site of inflammation and are associated to disease activity in patients 
with RA14. PGRN also plays a crucial role in chondrocyte proliferation15, differentiation and endochondral ossi-
fication of growth plate during development16,17. In addition, the group of Chuanju Liu reported that PGRN 
antagonised tumour necrosis factor α (TNF-α ) through binding to TNF receptors (TNFR), and exhibited an 
anti-inflammatory function, by suppressing the pro-inflammatory action of TNF-α in a arthritis murine mod-
els18,19. Additionally, these authors found that deficiency of PGRN led to spontaneous OA-like phenotype in 
‘aged’ mice. PGRN-deficient mice exhibited breakdown of cartilage structure, while local delivery of recombinant 
PGRN protein attenuated degradation of cartilage matrix in surgically induced OA models. Furthermore, PGRN 
plays a protective role by promoting anabolism of degenerative chondrocytes mainly through TNF receptor 2 
(TNFR2). TNF receptor 1 (TNFR1) binding to PGRN prevents the activation of the NF-κ B pathway by TNFα , 
which induces MMPs and ADAMTS, thus inhibiting cartilage degradation20.
Secreted pro-inflammatory cytokines, such as Interleukin 1β (IL1β ), are critical mediators implicated in OA 
pathophysiology, which make them primary targets for therapeutic strategies21. IL1β is released by synoviocytes, 
chondrocytes, and invading macrophages in inflamed joints and it is well-established that IL1β plays a pivotal 
role in the pathogenesis of OA22. IL1β triggers a cascade of cartilage damage events like the production of more 
pro-inflammatory cytokines, the synthesis of catabolic factors and the release of some inflammatory mediators 
such as prostaglandins produced by COX-2 and nitric oxide (NO) up-regulated by NOS223. Moreover, it has been 
suggested that IL1β induces the expression of the TNF-α gene in chondrocytes24 and upregulates the surface 
expression of TNFRs25.
Given that innate immune responses are important in the development of OA, the role of Toll like receptors 
(TLR) have been recently taken into account26. Among TLRs, TLR4 has been involved in OA27. TLR4 activa-
tion by lipopolysaccharide (LPS) involves the production of NO28, several pro-inflammatory cytokines29 and 
adipokines5,30 that may work together boosting cartilage degradation31. Previously, Yin et al. reported that 
PGRN-deficient macrophages challenged with LPS increase pro-inflammatory cytokine production32, and 
Hwang et al. showed that PGRN efficiently inhibited LPS-mediated pro-inflammatory signalling in endothelial 
cells through attenuation of the NF-κ B pathway, suggesting its beneficial anti-inflammatory effects33.
To the best of our knowledge, no data exist about PGRN effect on IL1β - or LPS-induced inflammatory 
responses of chondrocytes. Therefore, we investigated the effect of PGRN on the expression of some inflamma-
tory mediators and catabolic factors in IL1β - or LPS-stimulated chondrocytes for a better understanding of the 
underlying mechanisms implicated.
Materials and Methods
For experiments involving humans, all the methods were carried out in accordance with the approved guide-
lines. All experimental protocols were approved by the local ethics committee (SERGAS, Santiago University 
Clinical Hospital Ethics Committee (CAEIG Comité Autonómico de Ética da Investigación de Galicia 2014/310). 
Informed consent was obtained from all subjects.
Reagents. Fetal bovine serum (FBS), MTT dye, human transferrin, sodium selenite, ethylenediamine-
tetraacetic acid (EDTA) solution, mouse recombinant TNF-α , mouse and human recombinant IL1β and 
lipopolysaccharide (LPS) were obtained from Sigma (St. Louis MO, USA). Dulbecco’s modified Eagle’s medium 
(DMEM)/Ham’s F12 medium, l-glutamine, antibiotics and trypsin-EDTA were purchased from Lonza (Verviers, 
Belgium). Recombinant mouse PGRN (18–589) was purchased from Enzo Life Sciences (NYC, USA) and recom-
binant human PGRN (1–593) was from AdipoGen (Switzerland).
Cell culture and treatments. The murine chondrogenic cell line ATDC-5 (purchased from RIKEN Cell 
Bank, Tsukuba, Japan) was cultured in DMEM–Ham’s F-12 medium supplemented with 5% fetal bovine serum, 
10 μ g/ml human transferrin, 3·10−8 M sodium selenite, l-glutamine, and antibiotics (50 units/ml penicillin and 
50 μ g/ml streptomycin). Chondrogenic ATDC-5 cells were differentiated into mature chondrocytes. Briefly, cells 
were seeded at a density of 6·104/well in 6-well plates with the ATDC-5 standard media supplemented with insu-
lin (10 mg/mL). The differentiation media was replaced every two days for 14 days. Differentiation was qualita-
tively characterized by increased formation of cell nodules. In other experiments (data not shown), differentiation 
was further analyzed by sequential increase in the levels of type II collagen, aggrecan and type X collagen mRNA, 
as previously published34. The immortalized human juvenile costal chondrocyte cell line T/C-28a2 (a kind gift 
from Dr. M.B. Goldring, Hospital for Special Surgery, NYC, USA) was culture in DMEM–Ham’s F-12 medium 
supplemented with 10% fetal bovine serum, l-glutamine, and antibiotics (50 units/ml penicillin and 50 μ g/ml 
streptomycin). Primary chondrocytes were harvested from human OA articular cartilage samples obtained from 
articular joints of patients undergoing total knee replacement surgery (with permission from the local ethics 
committee (SERGAS, Santiago University Clinical Hospital Ethics Committee (CAEIG Comité Autonómico de 
Ética da Investigación de Galicia 2014/310) and informed consent was obtained from all patients participating 
in the study) as previously described35. Human chondrocytes were cultured in DMEM/Ham’s F12 medium sup-
plemented with 10% of fetal bovine serum, L-glutamine, and antibiotics (50 units/ml penicillin and 50 mg/ml 
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streptomycin). Cells were seeded in monolayer up to the high density and used in the first passage of culture in 
order to avoid dedifferentiation.
For RT-PCR and western blot, cells were seeded in 6-well plates until complete adhesion and then incubated 
overnight in serum-free conditions. Then, cells were treated as indicated in each case.
Cell viability. Cell viability was tested using the methyl-thiazolyl-tetrazolium (MTT) reagent to detect func-
tional mitochondria in living cells. Briefly, ATDC-5, ATDC-5 mature and T/C-28a2 cells (8·103/well) were seeded 
in 96-well plates. After overnight starvation, they were incubated with recombinant mouse and human PGRN for 
48 h in serum free medium. Doses of 100 and 200 ng/ml of PGRN reflect serum concentrations in healthy indi-
viduals36,37. Then, cells were incubated for 4 h with MTT reagent. After formazan salt was dissolved, absorbance 
was measured at 550 nm using a microtiter enzyme-linked immunosorbent assay reader (Multiskan EX; Thermo 
Labsystems). Cells cultured without PGRN were used to normalize cell viability status.
Nitrite assay. Nitrite accumulation was determined in the culture medium using the Griess reaction, as pre-
viously described31. Briefly, 100 μ l cell culture medium was mixed with 100 μ l Griess reagent (equal volumes of 1% 
[weight/vol] sulfanilamide in 5% [vol/vol] phosphoric acid and 0.1% [weight/vol] naphtylethylenediamine-HCl), 
incubated at room temperature for 10 min, and then the absorbance at 550 nm was measured using a microplate 
reader (Titertek-Multiscan, Labsystem, Helsinki, Finland). Fresh culture medium was used as blank in all of the 
experiments. The amount of nitrite in the samples (in micromolar units) was calculated from a sodium nitrite 
standard curve freshly prepared in culture medium.
RNA Isolation and Real-time Reverse Transcription-Polymerase Chain Reaction (RT-PCR). 
Mouse and human PGRN mRNA levels were determined using SYBR Green–based quantitative PCR. RNA 
was extracted using a NucleoSpin kit (Macherey-Nagel), according to the manufacturer’s instructions. For rel-
ative quantification, we performed an RT reaction using 1 mg of RNA with a Thermo Scientific Verso cDNA 
Synthesis Kit (42 °C for 30 min, followed by incubation at 95 °C for 2 min). RT-PCR was performed in a Stratagene 
MX3005P thermal cycler using a standard protocol (95 °C for 10 min followed by 40 cycles for 15 s of dena-
turation at 95 °C and 1 min annealing/extension at 60 °C), a SABiosciences Master Mix and specific primers 
(for mouse GAPDH, 140 bp, PPM02946E, reference position 309, GenBank accession no. NM_008084.2; for 
human GAPDH, 175 bp, PPH00150E, reference position 1287, GenBank accession no. NM_002046.3; for mouse 
PGRN, 121 bp, PPM24687A, reference position 1704, GenBank accession no. NM_008175.4; for human PGRN, 
130 bp, PPH02482B, reference position 1975, GenBank accession no. NM_002087.2; for mouse NOS2, 122 bp, 
PPM02928B, reference position 2728–2748, GenBank accession no. NM_010927.3; for mouse TNFRSF1A, 
156 bp, PPM03087D, reference position 1461, GenBank accession no. NM_ 011609.4; for mouse TNFα , 110 bp, 
PPM03113G, reference position 749, GenBank accession no. NM_013693). Results of comparative RT-PCRs were 
analyzed using MxPro software (Stratagene, CA, USA).
Protein extraction and Western blot analysis. After the cell treatment, cells were rapidly washed with 
ice-cold phosphate buffered saline and scraped in lysis buffer for protein extraction (10 mM Tris/HCl, pH 7.5, 
5 mM EDTA, 150 mM NaCl, 30 mM Sodium pyrophosphate, 50 mM sodium fluoride, 1 mM sodium orthovana-
date, 0.5% Triton X-100, 1 mM PMSF and protease inhibitor cocktail from Thermo Scientific). Lysed cells were 
centrifuged at 14.000 g for 20 min. SDS-PAGE and blotting procedure were carried on as previously described38. 
Immunoblots were incubated with the appropriate antibody (anti-PGRN diluted 1:1000, Santa Cruz, CA, USA; 
anti-NOS2 diluted 1:1000, Cell Signalling, MA, USA; anti-COX2 diluted 1:50, anti-VCAM-1 diluted 1:1000, 
Cell Signalling, MA, USA; anti-MMP13 diluted 1:500, Santa Cruz, CA, USA) and visualized with an Immobilon 
Western Detection kit (Millipore, MA) using anti-rabbit (GE Healthcare, UK) horseradish-peroxidise-labelled 
secondary antibody diluted 1:2000. To confirm equal loading in each sample, the membranes were stripped 
in stripping buffer (100 mM β -mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl pH 6.7) and re-blotted with 
anti-GAPDH antibody diluted 1:30000 (Sigma, MO, USA). The images were captured and analyzed with an EC3 
imaging system (UVP). Densitrometric analyses were performed using ImageJ software (National Institutes of 
Health, Bethesda, MD, USA).
siRNA-mediated gene silencing of TNFα receptor. In order to silence TNFR gene, we used the siRNA 
that targets TNFRSF1A (Integrated DNA Technologies, USA) and the siRNA negative control, that does not 
target any known sequence. Transfection with 10 nM of siRNA duplex was performed using the cationic lipid 
siLentFect (BioRad, CA, USA) according to the manufacturer’s recommendations. Cells were transfected for 48 h 
and then they were stimulated with 0.1 ng/ml of IL1β in presence or not of 200 ng/ml of PGRN for 48 h.
Statistical analysis. Data are reported as the mean ± standard error of the mean (SEM) and followed 
normal distribution of independent experiments, which were done at least three times, each time with at least 
three independent observations. Statistical analysis was performed using two-tailed Student’s t test and one-way 
ANOVA test followed by the Bonferroni’s test for multiple-comparisons using the Prism computerized package 
(GraphPad Software V.5, La Jolla, CA, USA). P-values less than 0.05 were considered significant.
Ethics approval. This study was conducted with the approval of the Santiago University Clinical Hospital 
Ethics Committee (CAEIG 2014/310).
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Results
Effect of PGRN on cell viability. First, in order to assess the effect on vitality of PGRN, we performed 
MTT assay in undifferentiated ATDC-5, in mature ATDC-5 and human T/C-28a2 chondrocytes. Treatment with 
increasing concentrations of PGRN for 48 hours showed no toxic effect on cell vitality (Sup. Fig. 1).
PGRN mRNA and protein production during ATDC-5 differentiation. To determine whether the 
levels of PGRN mRNA and protein change during chondrocyte differentiation, we differentiated ATDC-5 cells 
into mature and hypertrophic chondrocytes. As shown in Fig. 1, PGRN mRNA expression increased along dif-
ferentiation process of ATDC-5 cells. This increase is highly significant after 7, 14, and 21 days of differentiation 
in comparison to undifferentiated cells (Day 0) (Fig. 1, upper panel). This effect was observed also at protein 
expression (Fig. 1, lower panel).
PGRN expression in osteoarthritic and healthy tissues. Since local production of adipokines may 
have important pathological implications on cartilage homeostasis, we also assessed the expression of PGRN 
mRNA and protein levels in human primary chondrocytes, infrapatellar fat pad (IPFP) and synovium of OA 
patients, and compare this expression between OA subjects and healthy donors. As shown in Fig. 2, human 
primary chondrocytes, IPFP and synovium expressed efficiently PGRN. Moreover, PGRN expression was 
Figure 1. PGRN mRNA and protein expression during ATDC-5 differentiation after 7, 14, and 21 days. 
Values are the mean ± SEM of at least 4 independent experiments (**P < 0.01 vs. Ctrl, ***P < 0.001 vs. Ctrl.). 
Cell lysates underwent Western blot analysis using PGRN antibody. GAPDH was used as a loading control. The 
blots were run under the same experimental conditions. The full blots are shown in Supplementary Fig. 2. Blots 
are representative of at least 3 independent experiments.
Figure 2. Determination of PGRN mRNA and protein in healthy and osteoarthritis human tissues. PCR 
results were shown in fold change, where grey bars represent the PGRN mRNA expression in chondrocytes, 
infrapatellar fat pads (IPFPs) and synovial tissues obtained from osteoarthritis (OA) patients (*P < 0.05 vs. 
Ctrl.). PGRN protein expression was showed by representative western blots of 18 OA patients (age 52–73; mean 
BMI 28.4) and 6 healthy donors (age 23–50; mean BMI 23.4). GAPDH was used as loading control. Western 
blots have been run under the same experimental conditions. The full blots are shown in Supplementary Fig. 3.
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significantly higher in chondrocytes, IPFP and synovial tissues obtained from OA patients compared to those 
obtained from healthy donors.
Effect of pro-inflammatory cytokines and TLR-4 agonist on PGRN mRNA expression in ATDC5 
differentiated cells. To elucidate the pattern of PGRN expression under pro-inflammatory conditions, we 
treated differentiated ATDC-5 (14 days) cells with different doses of TNFα , IL1β , IL6 and LPS as a TLR-4 ago-
nist. These differentiated cells have a phenotype of adult mature chondrocytes and, in spite of its murine origin, 
have an identical behaviour to human cells, at last in terms of inflammatory mediators expression39. As shown in 
Fig. 3a, cells stimulated with TNFα during 24 h showed a marked increase in PGRN mRNA expression at 1 and 
5 ng/ml. A similar effect was observed when cells were stimulated with IL1β (0.05 and 0.1 ng/ml; Fig. 3b) during 
24 h. Nonetheless, neither IL6 nor LPS had significant effects on PGRN expression (Fig. 3c,d).
PGRN decreased IL1β induction of chondrocyte catabolism. In order to gain further insights into 
the potential pharmacological activity of PGRN, human primary chondrocytes were treated with IL1β (10 ng/ml) 
in presence or not of PGRN 200 ng/ml for 48 h. As shown in Fig. 4a, human primary chondrocytes challenged 
with IL1β , showed a strong accumulation of NO after 48 h in comparison to control unstimulated cells. However, 
treatment with recombinant PGRN significantly (P < 0.01) led to inhibition of IL1β -induced NO production, 
whereas PGRN per se did not affect basal NO production. Nitrite accumulation inhibition was further con-
firmed by western blot analysis of NOS type 2 (NOS2). PGRN was able to clearly inhibit NOS2 protein expression 
(Fig. 4b). Furthermore, since PGRN is supposed to prevent cartilage destruction in inflammatory arthritis medi-
ated by TNF-α , we examined the levels of catabolic biomarkers COX-2 and MMP13 in human primary chon-
drocytes challenged with IL1β . COX-2 and MMP13 protein levels were significantly increased after 48 h of IL1β 
treatment. However, PGRN significantly decreased IL1β -induced COX-2 and MMP13 expression (Fig. 4c,d). 
Moreover, since pro-inflammatory cytokines such as IL1β and TNFα are able to up-regulate VCAM-1 expression 
in primary cultures of human articular chondrocytes, we examined VCAM-1 protein levels after PGRN treat-
ment. IL1β is able to induce VCAM-1 expression. The treatment with PGRN produced a significant decrease of 
IL1β -induced VCAM-1 expression (Fig. 4e).
PGRN counteracted IL1β and LPS-driven NOS2 through TNFR1. It was reported that PGRN can 
competitively bind to TNFR1 and TNFR2 and prevents TNFα -mediated inflammation18. On the basis of above 
introduced results showing that PGRN counteracts IL1β -driven inflammatory response, we sought to investigate 
Figure 3. Mouse PGRN mRNA expression after TNFα, IL1β, IL6 and LPS treatment. (a) Cells were treated 
with TNFα 0.1, 1, 5 ng/ml, (b) IL1β 0.025, 0.05, 0.1 ng/ml, (c) IL6 0.1, 0.5, 1 ng/ml and (d) LPS 100, 250, 500 ng/
ml for 24 h. Values are the mean ± SEM of at least 3 independent experiments (**P < 0.01 vs. Ctrl, ***P < 0.001 
vs. Ctrl.).
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whether this anti-inflammatory effect of PGRN was mediated through TNFR. Firstly, we corroborated that PGRN 
was able to modulate IL1β or LPS-induced NO levels and NOS2 expression also in differentiated ATDC5 cells 
(Fig. 5a,b). Then, to determine whether the anti-inflammatory effect of PGRN was mediated through TNFR, we 
analysed the role of TNFR1 using a siRNA approach. Mature ATDC5 cells were transfected with siTNFR1 and 
then treated with IL1β or LPS in presence or not of PGRN (Fig. 5c,d). As shown in Fig. 5, TNFR1 siRNA knock-
down supressed the anti-inflammatory effect of PGRN under IL1β (panel c) or LPS (panel d) stimulation.
Discussion
The recently discovered adipokine PGRN has been matter of extensive studies in the last few years. The role of 
PGRN in inflammation has been only partially defined40. Although PGRN is one of the major anti-inflammatory 
molecules, it is possible that PGRN has dual roles in inflammation and might exert pro- or anti-inflammatory 
functions depending on different tissues. For instance, PGRN inhibits LPS-mediated IL-6, TNF-α , and MCP-1 
cytokine release from macrophages41, but PGRN is also the major adipokine involved in high-fat diet-induced 
insulin resistance by inducing up-regulation of IL-6 expression, a pro-inflammatory cytokine7. Chronic inflam-
mation in RA is mainly mediated by TNF-α 42. Recently, PGRN was recognized as a novel ligand of TNFR1/2. 
Actually, PGRN blocks TNF-α -mediated signalling pathways by competing with TNF-α binding to receptors in 
inflammatory arthritis murine models18,19.
However, there are currently no approaches in the literature evaluating PGRN action neither through IL1β 
nor through TLR4 activation in chondrocytes. Previously, Yin et al. reported that PGRN-deficient macrophages 
challenged with LPS increase pro-inflammatory cytokine production32, and Hwang et al. showed that PGRN 
efficiently inhibited LPS-mediated pro-inflammatory signalling in endothelial cells through attenuation of the 
NF-κ B pathway, suggesting its beneficial anti-inflammatory effects33. Thus, we have studied the effect of PGRN on 
the expression of some inflammatory mediators and catabolic factors in IL1β - or LPS-stimulated chondrocytes. 
To the best of our knowledge, this is the first experimental evidence that PGRN is able to reduce mediators of 
inflammation induced by IL1β or LPS in human chondrocytes.
Here we show for the first time, that PGRN mRNA and protein expression is detected in human infrapatellar 
fat pads (IPFPs) and synovial tissues. Moreover, PGRN expression was significantly higher in chondrocytes, IPFP 
and synovial tissues obtained from OA patients compared to these tissues obtained from healthy donors. Our 
Figure 4. PGRN suppressed IL1-β induction of chondrocyte catabolism. (a) Cells were treated with 10 ng/
ml of IL1β , in presence or absence of 200 ng/ml of PGRN for 48 h. Culture medium was subsequently analyzed 
for nitrite levels. NO concentration (μ M) was determined using the Griess reaction. Values are the mean ± SEM 
of at least 3 independent experiments (**P < 0.01 vs. IL1β ) (a, upper panel). Cell lysates underwent Western 
blotting analysis under the same condition (a, lower panel). After transferring the blots onto PVDF membranes, 
we cropped the targeted blots according to referenced indicating markers, and then targeted proteins were 
immunoblotted with NOS2, COX-2, MMP13 and VCAM-1 antibodies. GAPDH was used as a loading control. 
Blots are representative of at least 3 independent experiments. (b–e) Western blot densitometric analysis (n = 3; 
***P < 0.001 PGRN + IL1β vs. IL1β ).
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findings are in agreement with previous results of increased PGRN mRNA and protein expression in OA and RA 
cartilage described by Guo et al.8 Recently, it was reported the expression profile of PGRN in another cartilage 
degenerative disease, such as disc degenetation. PGRN levels were also elevated in intervertebral discs during 
aging, and PGRN knockout mice developed an early onset of degeneration in intervertebral cartilage43.
Our work makes another novel observation, that PGRN mRNA expression was increased during the process 
of ATDC-5 cell differentiation into mature chondrocytes. These data suggested that this adipokine might play a 
role in the complex mechanisms of chondrocyte development and differentiation. PGRN might be a marker of 
late-phase chondrogenic differentiation. To this regard, the group of Chuan-ju Liu reported that PGRN was a key 
downstream molecule of BMP2, and it was required for BMP2-mediated chondrocyte differentiation through 
Erk1/2 signaling17. They also showed that PGRN was required for BMP-2 induction of osteoblastogenesis and 
ectopic bone formation10. Moreover, we observed elevated PGRN levels also in hypertrophic chondrocytes, those 
localized above subchondral bone. However, in PGRN −/− mice, Zhao et al. revealed osteophyte formation and 
ectopic subchondal sclerosis. These results indicated disorder of bone metabolism in cartilage and subchondral 
bone of these mice, suggesting a role for PGRN in the regulation of subchondral bone turnover20.
Although several suppositions postulated that PGRN might be strongly influenced by the inflammatory 
“milieu”, here we show clear experimental evidence that classic cytokines or activation of TLR4 by LPS in 
Figure 5. PGRN counteracted IL1β and LPS-induced nitric oxide (NO) production and inhibited NOS2 
expression in cultured ATDC-5 cells, at least in part, through TNFR1. (a,b) Cells were treated with 0.1 ng/ml 
of IL1β (a) and 250 ng/ml of LPS (b) alone or in combination PGRN (200 ng/ml) during 48 h. Culture medium 
was subsequently analyzed for nitrite levels. NO concentration (μ M) was determined using the Griess reaction. 
Values are the mean ± SEM of at least 3 independent experiments (a) **P < 0.01 PGRN + IL1β vs. IL1β ;  
(b) **P < 0.01 PGRN + LPS vs. LPS). Cell lysates underwent Western blotting analysis using NOS2 antibody. 
GAPDH was used as a loading control. The blots were run under the same experimental conditions. The full 
blots are shown in Supplementary Fig. 3. Blots are representative of at least 3 independent experiments. (c,d) 
Cells were transfected with negative control siRNA or TNFR1-targeted siRNA (siTNFR1) and stimulated with 
0.1 ng/ml of IL1β (c) and 250 ng/ml of LPS (d) in absence or presence of PGRN 200 ng/ml for 48 h. Relative 
mRNA levels of NOS2 were measure by RT-PCR. Values are the mean ± SEM of at least 3 independent 
experiments (c) **P < 0.01 siC- PGRN + IL1β vs. siC- IL1β ; (d) **P < 0.01 siC- PGRN + LPS vs. siC-LPS).
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chondrocytes are able to strongly influence PGRN levels. These findings suggest that PGRN induction by TNFα 
and IL1β released from joint tissues may be an adaptive response to the inflammatory state.
Since IL1β plays a pivotal role in the pathogenesis of OA22, counteracting its pro-inflammatory effects with 
PGRN might be an interesting therapeutic strategy. Actually, we assessed whether PGRN was able to inhibit 
IL1β -mediated pro-inflammatory response. Our data clearly demonstrate that PGRN strongly attenuated IL1β 
driven inflammatory markers, such as NO production, NOS2, COX2 and VCAM-1 expression, as well as cata-
bolic markers of cartilage breakdown, such as MMP13. Moreover, we showed clear evidence that PGRN effect 
upon IL1β -driven NOS2 induction is mediated, at least in part, through TNFR1. Actually, by down-regulating 
TNFR1 expression through RNA interference, the anti-inflammatory role of PGRN counteracting IL1β was 
totally blocked, suggesting that PGRN is working via TNFα signalling through binding to TNFR.
Here we also show clear evidence that PGRN is able also to modulate LPS-driven NOS2 induction. This effect 
is likely to be mediated, at least in part, through TNFR1. Actually, by down-regulating TNFR1 expression through 
siRNA, the anti-inflammatory role of PGRN was totally blocked. Our results are in line with other published 
results suggesting that PGRN is able to inhibit LPS-mediated pro-inflammatory signalling32,33. Thus, at the func-
tional aspect, the activity of PGRN, and its increased expression observed upon IL-1β and TNF-alpha treatment 
could mediate and sustain clear pro-anabolic and anti-inflammatory pathways. Nonetheless, the relevance of 
these data in the pathophysiology of osteoarthritis or other chronic rheumatic diseases should be supported by 
clinical data that at present are non-existent.
In conclusion, on the basis of our data and on previous published results, PGRN in articular joint cells could 
limit expression of inflammatory mediators, adhesion molecules and enzymes involved in cartilage breakdown 
triggered by cytokines and LPS that ultimately compromise cell survival and tissue function. PGRN may repre-
sent a novel key molecule coupling cartilage metabolism with inflammation to switch physiologic and clinical 
phenotypes. Thus, targeted strategies aimed to increase PGRN levels appeals to be an attractive therapeutic strat-
egy for OA, which could be potentially achieved through multiple ways including life style modifications and 
pharmacological approaches.
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